Tirzepatide Insurance Coverage Guide

Can Medicare members get Zepbound for $50?

Yes, if they qualify for the Medicare GLP-1 Bridge, a CMS demonstration running July 1, 2026 through December 31, 2027. Program terms, checked November 4, 2026:

• Which tirzepatide: Zepbound KwikPen only. The Zepbound vial and Mounjaro are not on the Bridge list. Wegovy and Foundayo are the other covered drugs.
• Cost: a $50 copay, with no Part D deductible.
• Limits: the $50 does not count toward your true out-of-pocket total, and Extra Help (the Low-Income Subsidy) does not lower it.
• Approval: your prescriber sends a prior authorization to a CMS central processor. Your Part D plan does not have to opt in.
• Who: adults aged 18 and up whose prescription is for weight reduction and who meet BMI and clinical criteria.
• Where to check: Medicare.gov/glp1bridge or 1-800-MEDICARE.

If you buy Zepbound vials now, ask your prescriber whether switching to the KwikPen makes sense for the Bridge. LillyDirect charges the same for both forms.

Medicare Part D in 2027: what applies to tirzepatide

• The annual Part D out-of-pocket cap goes to $2,400 in 2027.
• Most Part D plans continue to leave out weight-loss-only prescriptions, so the Bridge remains the main Medicare route for Zepbound prescribed for weight.
• Sleep apnea is a separate FDA-approved use. A Part D plan may cover Zepbound for moderate to severe OSA in adults with obesity under its own formulary rules.
• Mounjaro for type 2 diabetes stays under regular Part D coverage. The Bridge does not serve people whose qualifying condition is diabetes. In its October 29, 2026 results, Lilly reported FDA approval of Mounjaro to reduce cardiovascular risk in type 2 diabetes.
• The Medicare negotiated prices starting in 2027 apply to Ozempic, Wegovy and Rybelsus, not to tirzepatide.
• The window to pick a 2027 plan closes December 7, 2026; it opened October 15.

Employer plans, CVS Caremark and Medicaid

CVS Caremark. Since October 1, 2026, Caremark has offered Zepbound on commercial formularies again as an additional preferred option, but only where the plan sponsor chose to take part. Caremark members can ask HR whether their employer made that choice.

Employers. WTW's survey published October 28, 2026 found that the share of employers covering GLP-1s for weight loss slipped to 53% from 57%. Of those still covering them, 16% are weighing an exit, compared with 9% before. 8% of employers already use a direct-to-consumer purchase model and 28% are planning or considering one.

Medicaid. Obesity coverage shrank in 2026. KFF counted 13 state Medicaid programs covering GLP-1s for obesity in January 2026, compared with 16 before. Four states (California, New Hampshire, Pennsylvania, South Carolina) dropped coverage on January 1, 2026, and Massachusetts (MassHealth) followed on July 3, 2026. States may join the Medicaid part of CMS's BALANCE model on a rolling basis until January 1, 2027.

If your plan says no

1. Read the denial letter for the exact reason, such as a missing BMI, step therapy or a plan exclusion.
2. Ask your prescriber to resubmit with the missing records, or to request an exception.
3. File an internal appeal before the deadline in the letter, then ask for an external review if it is upheld.

Paying without insurance, as of November 4, 2026:

Compounded tirzepatide lacks FDA approval, and insurers do not pay for it; a licensed clinician decides whether it fits you. Compare more programs in the tirzepatide price index.